Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

961 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).
Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, Heß G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Röth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G. Fritsch K, et al. Among authors: binder m. Leukemia. 2017 Apr;31(4):846-852. doi: 10.1038/leu.2016.334. Epub 2016 Nov 15. Leukemia. 2017. PMID: 27843136 Free PMC article. Clinical Trial.
High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G. Kasenda B, et al. Among authors: binder m. Leukemia. 2017 Dec;31(12):2623-2629. doi: 10.1038/leu.2017.170. Epub 2017 May 31. Leukemia. 2017. PMID: 28559537 Clinical Trial.
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma.
Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Mellors PW, et al. Among authors: binder m. Leuk Lymphoma. 2019 Dec;60(12):2960-2967. doi: 10.1080/10428194.2019.1613536. Epub 2019 May 16. Leuk Lymphoma. 2019. PMID: 31096812
Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients.
Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, Carr RM, Binder M, Finke CM, Gangat N, Al-Kali A, Begna KH, Reichard KK, Ketterling RP, Al Ali NH, Vafaii P, Zhang L, Padron E, Talati C, Patnaik MM. Mangaonkar AA, et al. Among authors: binder m. Leukemia. 2020 Feb;34(2):656-661. doi: 10.1038/s41375-019-0574-x. Epub 2019 Sep 11. Leukemia. 2020. PMID: 31511613 No abstract available.
Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients.
Buradkar A, Bezerra E, Coltro G, Lasho TL, Finke CM, Gangat N, Carr RM, Binder M, Mangaonkar AA, Ketterling R, Khan S, Rodriguez V, Tefferi A, Patnaik MM. Buradkar A, et al. Among authors: binder m. Leukemia. 2021 Feb;35(2):644-649. doi: 10.1038/s41375-020-0889-7. Epub 2020 Jun 8. Leukemia. 2021. PMID: 32513965 No abstract available.
Mortality trends in multiple myeloma after the introduction of novel therapies in the United States.
Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, Lacy MQ, Gertz MA, Hayman SR, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Gonsalves WI, Russell S, Lin Y, Siddiqui M, Kyle RA, Dispenzieri A, Kumar SK. Binder M, et al. Leukemia. 2022 Mar;36(3):801-808. doi: 10.1038/s41375-021-01453-5. Epub 2021 Oct 26. Leukemia. 2022. PMID: 34702976
Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment.
Claveau JS, Murray DL, Dispenzieri A, Kapoor P, Binder M, Buadi F, Dingli D, Fonder A, Gertz M, Gonsalves W, Hayman S, Hobbs M, Hwa YL, Kourelis T, Lacy M, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar V, Kumar SK. Claveau JS, et al. Among authors: binder m. Leukemia. 2023 Jan;37(1):1-4. doi: 10.1038/s41375-022-01779-8. Epub 2022 Dec 8. Leukemia. 2023. PMID: 36482129 No abstract available.
Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis.
Lasho T, Finke C, Timm M, Tefferi A, Mangaonkar A, Olteanu H, Reichard K, Ketterling R, Gangat N, Xie Z, Fernandez J, Chia N, Gaspar-Maia A, Binder M, Patnaik MM. Lasho T, et al. Among authors: binder m. Leukemia. 2023 Jun;37(6):1384-1387. doi: 10.1038/s41375-023-01887-z. Epub 2023 Mar 25. Leukemia. 2023. PMID: 36966263 No abstract available.
Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures.
Zanwar S, Gertz MA, Muchtar E, Buadi FK, Kourelis T, Gonsalves W, Go RS, Hayman S, Kapoor P, Binder M, Cook J, Dingli D, Leung N, Lin Y, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S, Dispenzieri A. Zanwar S, et al. Among authors: binder m. Leukemia. 2024 Apr 9. doi: 10.1038/s41375-024-02243-5. Online ahead of print. Leukemia. 2024. PMID: 38594348 No abstract available.
961 results